This is a working overview of investigational status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Ronnie O'Sullivan wins the 2024 Masters after beating Ali Carter, making him both the youngest and oldest winner in the tournament's history. He won his first title in the 1995 Masters when he was 19 years old. 29 years later, he wins his eighth at the age of 48. 15 January The portrait of King Charles III for use on public buildings, such as courts and government offices is unveiled. Another week of strike action is announced by the ASLEF train drivers union, to run from Tuesday 30 January until Monday 5 February. The Home Office announces that it will proscribe the radical Islamist group Hizb ut-Tahrir as a terrorist organisation, accused of praising the Hamas attacks. A review into investigations conducted by Greater Manchester Police between 2004 and 2019 finds that girls were "left at the mercy" of paedophile grooming gangs for several years because of failings by senior police and council bosses. Alison Phillips confirms she will stand down as editor of the Daily Mirror at the end of January, having been in the role since 2018. 16 January Schools are closed and commuters face disruption following snowfall across parts of the UK. Lee Anderson and Brendan Clarke-Smith resign their positions as Deputy Chairmen of the Conservative Party, after saying they would back rebel amendments on the Rwanda bill. Jane Stevenson also resigns as a Parliamentary Private Secretary so she can vote for the amendment.
=== Gas exchange === The major function of the lungs is gas exchange between the lungs and the blood. The alveolar and pulmonary capillary gases equilibrate across the thin blood–air barrier. This thin membrane (about 0.5 –2 μm thick) is folded into about 300 million alveoli, providing an extremely large surface area (estimates varying between 70 and 145 m2) for gas exchange to occur.
PMID 1116247. Daly, M.M. (January 1976). "Effects of age and hypertension on utilization of glucose by rat aorta". American Journal of Physiology. 230 (1): 30–33. doi:10.1152/ajplegacy.1976.230.1.30. PMID 1251907. Park, Sung Suh; Kikkawa, Yutaka; Goldring, Irene P.; Daly, Marie M.; Zelefsky, Melvin; Shim, Chang; Spierer, Morris; Morita, Toyohiko (June 1, 1977). "An Animal Model of Cigarette Smoking in Beagle Dogs Correlative Evaluation of Effects on Pulmonary Function, Defense, and Morphology". American Review of Respiratory Disease. 115 (6): 971–979. doi:10.1164/arrd.1977.115.6.971 (inactive 12 July 2025). PMID 262108. Retrieved 8 November 2018.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link) Daly, Marie M.; Seifter, Sam (August 1980). "Uptake of creatine by cultured cells". Archives of Biochemistry and Biophysics. 203 (1): 317–324. doi:10.1016/0003-9861(80)90182-4. PMID 7406503. Daly, Marie M. (February 1, 1985). "Guanidinoacetate methyltransferase activity in tissues and cultured cells". Archives of Biochemistry and Biophysics. 236 (2): 576–584. doi:10.1016/0003-9861(85)90661-7. PMID 3970526.
Sources: en.wikipedia.org
=== Pharmacodynamics === Cyclofenil is a SERM, or a mixed agonist and antagonist of the estrogen receptors (ERs). It is described as a relatively weak/mild SERM. The medication is generally less effective than other SERMs. The medication is an "impeded estrogen" and is thought to work as a progonadotropin by blocking the actions of estrogens in the pituitary gland and hypothalamus, thereby disinhibiting release of the gonadotropins luteinizing hormone and follicle-stimulating hormone. In men, cyclofenil can increase testosterone levels due its progonadotropic effects.
Clear Lake Audiotorium is a six-track promo EP by De La Soul given out to A-list DJs in 1994, the catalog number is TB 1093 (Side A, "THIS SIDE" is TB 1093 A and Side B "OTHER SIDE" is TB 1093 B). It was composed of four tracks from the group's album Buhloone Mindstate and two non-album tracks—"Sh.Fe.Mc's" featuring A Tribe Called Quest, and "Stix & Stonz" featuring The Fearless Four, Grandmaster Caz, and Prince Whipper Whip. With only 500 copies pressed (vinyl and CD), Clear Lake Audiotorium remains one of the most sought-after De La Soul releases to date. Originally pressed on clear/light green vinyl and packaged in a clear plastic sleeve, the record has since been bootlegged on black vinyl. On March 7, 2025, exactly 31 years after its original release, the EP was released officially on streaming releases, alongside a limited physical re-release.
Acceptance sampling procedures became common during World War II. Sampling plans, such as MIL-STD-105, were developed by Harold F. Dodge and others and became frequently used as standards. More recently, quality assurance broadened the scope beyond final inspection to include all aspects of manufacturing. Broader quality management systems include methodologies such as statistical process control, HACCP, six sigma, and ISO 9000. Some use of acceptance sampling still remains.
Sources: en.wikipedia.org
=== Legal status === Dasiglucagon was designated an orphan drug by the FDA in August 2017. In May 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zegalogue, intended for the treatment of severe hypoglycaemia in people with diabetes. The applicant for this medicinal product is Zealand Pharma A/S. Dasiglucagon was approved for medical use in the European Union in July 2024.
Some brands of soy sauce are made from acid-hydrolyzed soy protein instead of brewed with a traditional culture. This takes about three days. Although they have a different flavor, aroma, and texture when compared to brewed soy sauces, they can be produced more quickly and cheaply, and also have a longer shelf life and are usually made for these reasons. The clear plastic packets of dark sauce common with Chinese-style take-out food typically use a hydrolyzed vegetable protein formula. Some higher-priced hydrolyzed vegetable protein products with no added sugar or colorings are sold as low-sodium soy sauce alternatives called "liquid aminos" in health food stores, similar to the way salt substitutes are used. These products are, however, not necessarily low in sodium.
Finally, in addition to stoking international concern, the deployment of the military to quell the uprising was a polarising issue among the government's white constituents. The white liberal Progressive Federal Party had warned from the outset of Operation Palmiet that an expanded role for SADF in domestic policing would increase resistance to conscription, and this warning was borne out in the subsequence increase in conscientious objections and the rise of the End Conscription Campaign.
monocyte A type of large leukocyte of the mononuclear phagocyte system in mammals, characterized by pale-staining cytoplasm and a kidney-shaped or horseshoe-shaped nucleus. Monocytes are derived from pluripotent stem cells in bone marrow and become macrophages in other tissues.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.